An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

Seoul National University

Status: Completed

Conditions: Neoadjuvant; Pancreatic Cancer

Treatments: Drug: Neoadjuvant treatment

Study type: Observational

Funder types: Other

Identifiers

NCT06129812

NAT in resectable PDAC

Details and patient eligibility

About

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

Full description

The 1,132 patients with resectable or borderline resectable PDAC who underwent surgery between 2007 and 2021 were retrospectively reviewed. Patients with resectable PDAC without contact of major vessels (R-no contact) (n=651), with contact of portal vein or superior mesenteric vein (PV/SMV) ≤180° (R-contact) (n=306), and borderline resectable PDAC without arterial involvement (BR-V) (n=175) were analyzed.

Enrollment: 1,132 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC)
• Between January 2007 and June 2021 at Seoul National University Hospital

Exclusion criteria

• Patients who had borderline resectable PDAC with arterial invasion
• Patients who received chemotherapy as initial treatment and did not undergo surgery
• Incomplete follow-up data for analysis

Trial design

1,132 participants in 3 patient groups

resectable PDAC with no contact to major vessels (R-no contact)

Treatment:

Drug: Neoadjuvant treatment

resectable PDAC with contact PV/SMV of ≤180° (R-contact)

Treatment:

Drug: Neoadjuvant treatment

borderline resectable PDAC with PV/SMV contact >180° and without arterial involvement (BR-V)

Treatment:

Drug: Neoadjuvant treatment